391 related articles for article (PubMed ID: 31120927)
1. Norcantharidin regulates ERα signaling and tamoxifen resistance via targeting miR-873/CDK3 in breast cancer cells.
Zhang X; Zhang B; Zhang P; Lian L; Li L; Qiu Z; Qian K; Chen A; Liu Q; Jiang Y; Cui J; Qi B
PLoS One; 2019; 14(5):e0217181. PubMed ID: 31120927
[TBL] [Abstract][Full Text] [Related]
2. MiR-873 regulates ERα transcriptional activity and tamoxifen resistance via targeting CDK3 in breast cancer cells.
Cui J; Yang Y; Li H; Leng Y; Qian K; Huang Q; Zhang C; Lu Z; Chen J; Sun T; Wu R; Sun Y; Song H; Wei X; Jing P; Yang X; Zhang C
Oncogene; 2015 Jul; 34(30):3895-907. PubMed ID: 25531331
[TBL] [Abstract][Full Text] [Related]
3. miR-125a-3p inhibits ERα transactivation and overrides tamoxifen resistance by targeting CDK3 in estrogen receptor-positive breast cancer.
Zheng L; Meng X; Li X; Zhang Y; Li C; Xiang C; Xing Y; Xia Y; Xi T
FASEB J; 2018 Feb; 32(2):588-600. PubMed ID: 28939591
[TBL] [Abstract][Full Text] [Related]
4. The ERα-miR-575-p27 feedback loop regulates tamoxifen sensitivity in ER-positive Breast Cancer.
Liu SS; Li Y; Zhang H; Zhang D; Zhang XB; Wang X; Yu Y
Theranostics; 2020; 10(23):10729-10742. PubMed ID: 32929377
[No Abstract] [Full Text] [Related]
5. Loss of Estrogen-Regulated
Zhang W; Wu M; Chong QY; Zhang M; Zhang X; Hu L; Zhong Y; Qian P; Kong X; Tan S; Li G; Ding K; Lobie PE; Zhu T
Cancer Res; 2018 Sep; 78(17):4915-4928. PubMed ID: 29945962
[TBL] [Abstract][Full Text] [Related]
6. Norcantharidin modulates the miR-30a/Metadherin/AKT signaling axis to suppress proliferation and metastasis of stromal tumor cells in giant cell tumor of bone.
Chen F; Wang S; Wei Y; Wu J; Huang G; Chen J; Shi J; Xia J
Biomed Pharmacother; 2018 Jul; 103():1092-1100. PubMed ID: 29710674
[TBL] [Abstract][Full Text] [Related]
7. Loss of Rho GDIα and resistance to tamoxifen via effects on estrogen receptor α.
Barone I; Brusco L; Gu G; Selever J; Beyer A; Covington KR; Tsimelzon A; Wang T; Hilsenbeck SG; Chamness GC; Andò S; Fuqua SA
J Natl Cancer Inst; 2011 Apr; 103(7):538-52. PubMed ID: 21447808
[TBL] [Abstract][Full Text] [Related]
8. CUL4B renders breast cancer cells tamoxifen-resistant via miR-32-5p/ER-α36 axis.
Wang Y; Pan X; Li Y; Wang R; Yang Y; Jiang B; Sun G; Shao C; Wang M; Gong Y
J Pathol; 2021 Jun; 254(2):185-198. PubMed ID: 33638154
[TBL] [Abstract][Full Text] [Related]
9. miR-190 enhances endocrine therapy sensitivity by regulating SOX9 expression in breast cancer.
Yu Y; Yin W; Yu ZH; Zhou YJ; Chi JR; Ge J; Cao XC
J Exp Clin Cancer Res; 2019 Jan; 38(1):22. PubMed ID: 30658681
[TBL] [Abstract][Full Text] [Related]
10. miR-489 Confines Uncontrolled Estrogen Signaling through a Negative Feedback Mechanism and Regulates Tamoxifen Resistance in Breast Cancer.
Soni M; Saatci O; Gupta G; Patel Y; Keerthi Raja MR; Li J; Liu X; Xu P; Wang H; Fan D; Sahin O; Chen H
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897675
[TBL] [Abstract][Full Text] [Related]
11. MiRNA-27a sensitizes breast cancer cells to treatment with Selective Estrogen Receptor Modulators.
Ljepoja B; García-Roman J; Sommer AK; Wagner E; Roidl A
Breast; 2019 Feb; 43():31-38. PubMed ID: 30415143
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer.
Zhao JJ; Lin J; Yang H; Kong W; He L; Ma X; Coppola D; Cheng JQ
J Biol Chem; 2008 Nov; 283(45):31079-86. PubMed ID: 18790736
[TBL] [Abstract][Full Text] [Related]
13. Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells.
Basak P; Chatterjee S; Bhat V; Su A; Jin H; Lee-Wing V; Liu Q; Hu P; Murphy LC; Raouf A
Cell Physiol Biochem; 2018; 51(4):1518-1532. PubMed ID: 30497079
[TBL] [Abstract][Full Text] [Related]
14. A novel tumor suppressor ZBTB1 regulates tamoxifen resistance and aerobic glycolysis through suppressing
Zhang P; Yang Y; Qian K; Li L; Zhang C; Fu X; Zhang X; Chen H; Liu Q; Cao S; Cui J
J Biol Chem; 2020 Oct; 295(41):14140-14152. PubMed ID: 32690611
[TBL] [Abstract][Full Text] [Related]
15. HOXB7 Is an ERα Cofactor in the Activation of HER2 and Multiple ER Target Genes Leading to Endocrine Resistance.
Jin K; Park S; Teo WW; Korangath P; Cho SS; Yoshida T; Győrffy B; Goswami CP; Nakshatri H; Cruz LA; Zhou W; Ji H; Su Y; Ekram M; Wu Z; Zhu T; Polyak K; Sukumar S
Cancer Discov; 2015 Sep; 5(9):944-59. PubMed ID: 26180042
[TBL] [Abstract][Full Text] [Related]
16. Decreased BRCA1 confers tamoxifen resistance in breast cancer cells by altering estrogen receptor-coregulator interactions.
Wen J; Li R; Lu Y; Shupnik MA
Oncogene; 2009 Jan; 28(4):575-86. PubMed ID: 18997820
[TBL] [Abstract][Full Text] [Related]
17. E2F7 overexpression leads to tamoxifen resistance in breast cancer cells by competing with E2F1 at miR-15a/16 promoter.
Chu J; Zhu Y; Liu Y; Sun L; Lv X; Wu Y; Hu P; Su F; Gong C; Song E; Liu B; Liu Q
Oncotarget; 2015 Oct; 6(31):31944-57. PubMed ID: 26397135
[TBL] [Abstract][Full Text] [Related]
18. Trichostatin A and Tamoxifen inhibit breast cancer cell growth by miR-204 and ERα reducing AKT/mTOR pathway.
Liu J; Li Y
Biochem Biophys Res Commun; 2015 Nov; 467(2):242-7. PubMed ID: 26436206
[TBL] [Abstract][Full Text] [Related]
19. Tamoxifen Resistance in Breast Cancer Is Regulated by the EZH2-ERα-GREB1 Transcriptional Axis.
Wu Y; Zhang Z; Cenciarini ME; Proietti CJ; Amasino M; Hong T; Yang M; Liao Y; Chiang HC; Kaklamani VG; Jeselsohn R; Vadlamudi RK; Huang TH; Li R; De Angelis C; Fu X; Elizalde PV; Schiff R; Brown M; Xu K
Cancer Res; 2018 Feb; 78(3):671-684. PubMed ID: 29212856
[TBL] [Abstract][Full Text] [Related]
20. HOXB13 mediates tamoxifen resistance and invasiveness in human breast cancer by suppressing ERα and inducing IL-6 expression.
Shah N; Jin K; Cruz LA; Park S; Sadik H; Cho S; Goswami CP; Nakshatri H; Gupta R; Chang HY; Zhang Z; Cimino-Mathews A; Cope L; Umbricht C; Sukumar S
Cancer Res; 2013 Sep; 73(17):5449-58. PubMed ID: 23832664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
